WO2014060596A1 - Procédé de préparation de dérivés d'indole - Google Patents

Procédé de préparation de dérivés d'indole Download PDF

Info

Publication number
WO2014060596A1
WO2014060596A1 PCT/EP2013/071890 EP2013071890W WO2014060596A1 WO 2014060596 A1 WO2014060596 A1 WO 2014060596A1 EP 2013071890 W EP2013071890 W EP 2013071890W WO 2014060596 A1 WO2014060596 A1 WO 2014060596A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
defined above
alkyl
acid
Prior art date
Application number
PCT/EP2013/071890
Other languages
English (en)
Inventor
Paolo Maragni
Mariella PATTAROZZI
Raffaella Volpicelli
Mauro Maffini
Alberto Guidi
Elisa Melotto
Livius Cotarca
Massimo Verzini
Original Assignee
Zach System S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zach System S.P.A. filed Critical Zach System S.P.A.
Publication of WO2014060596A1 publication Critical patent/WO2014060596A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention relates to a process for preparing indole derivatives as intermediates for producing Chemo-attractant Receptor-homologous receptor expressed on Th2 cells (CRTH2) receptor antagonists useful for the treatment of various prostaglandin-mediated diseases and disorders.
  • CRTH2 Chemo-attractant Receptor-homologous receptor expressed on Th2 cells
  • CRTH2 is one of the two high-affinity transmembrane receptors for prostaglandin d2 (PGD2) that have been identified to date.
  • PGD2 has been implicated as a mediator of allergic inflammation and diseases including asthma, allergic rhinitis, and atopic dermatitis.
  • CRTH2 receptor antagonist for the potential treatment of respiratory disease.
  • WO 2010/099039 provides other compounds active as CRTH2 receptor antagonists having a 1,2,3-triazole group directly linked to the tricyclic ring system, such as, for example, the compounds of formula la: (la)
  • Rj a is selected from H, halogen, -OCi_ 6 alkyl, -0-haloCi_ 6 alkyl, -C i_ 6 alkyl, haloCi_ 6 alkyl, optionally substituted aryl and -(Ci_ 3 alkylene)-optionally substituted aryl; and Yi is selected from optionally substituted aryl and - C(R 2 )(R 3 )(R 4 ); R2 is selected from H, -Ci_ 6 alkyl optionally substituted with halogen, -OH or -NHS0 2 CH 3 , -OH, -OCi_ 6 alkyl, -S(0)nCi_ 6 alkyl, -CN, optionally substituted aryl, optionally substituted -O-aryl and optionally substituted heteroaryl, wherein n is 0, 1 or 2; R3 is selected from H, -Ci_ 6 alkyl, -Ci_ 6 haloalkyl
  • the compound of formula (8 A) can be prepared following the teachings of EXAMPLE 8A of WO 2010/099039.
  • the present invention relates to a novel alternative process for the preparation of an "alcohol" intermediate of formula (I)
  • R is Ci_ 4 alkyl and its use in the manufacture of the compound of formula (8A), which can be useful for preventing, treating or ameliorating prostaglandin mediated disease or disorder in a mammalian, especially a human subject.
  • the present invention refers to a process for preparing a compound of formula (I)
  • R is Ci_ 4 alkyl, which comprises:
  • R is as defined above;
  • X is an halogen atom including Bromine, Chlorine and Iodine
  • PG is a hydroxyl protecting group
  • R is as defined above
  • Ri Ci_ 4 alkyl or R and Ri taken together are a group -(CH2) n - wherein n is 2 or 3, to obtain a compound of formula (V)
  • Ci_ 4 alkyl refers to alkyl moieties including methyl, ethyl, propyl (n- propyl or isopropyl) and butyl (n-butyl, isobutyl or t-butyl).
  • R is methyl or ethyl.
  • protecting group means a moiety that prevents or blocks reaction of a particular chemically reactive functional group in a molecule under certain reaction conditions. Such protecting groups are well-known to those skilled in the art and are described, for example, in Protective Groups in Organic Synthesis (T. Green and P. Wuts; 4th Edition; John Wiley and Sons, 2006).
  • hydroxyl protecting group means a protecting group suitable for preventing undesirable reactions at a hydroxy group.
  • Representative hydroxyl protecting groups include, but are not limited to, acetyl (Ac), formyl, benzoyl (Bz), benzyl (Bn, Bnl), benzyloxymethyl (BOM), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), diphenylmethyl (DPM), beta methoxyethoxymethyl ether (MEM), dimethoxytrityl [bis-(4- methoxyphenyl)phenylm ethyl, DMT], methoxymethyl ether (MOM), methoxytrityl [(4- methoxyphenyl)diphenylmethyl, MMT), p-methoxybenzyl ether (PMB), methylthiomethyl ether, pivaloyl (Piv), tetrahydropyranyl (THP), trity
  • mineral acid means an inorganic acid which is an acid derived from one or more inorganic compounds.
  • Representative “mineral acid” include, but are not limited to, sulphuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid and polyphosphoric acid.
  • organic acid means an organic compound with acidic properties including carboxylic acids, whose acidity is associated with their carboxyl group -COOH and sulfonic acids, containing the group -S0 2 OH.
  • an organic acid is, preferably, trifluoroacetic acid, methanesulfonic acid or p-toluenesulfonic acid, more preferably p-toluenesulfonic acid also in mixture with residual trifluoroacetic acid.
  • step i) can be carried out, for example, by reacting the compound of formula (II) with an alcohol of formula R-OH wherein R is defined above in the presence of catalytic amounts of a "mineral acid” or an "organic acid", which are defined above.
  • the reaction under step ii) can be carried out, for example, by reacting the compound of formula (III) with a suitable base in a polar aprotic solvent, followed by addition of a compound of formula (IV).
  • suitable bases include, but are not limited to, sodium hydride, potassium tert-butoxide, sodium tert-butoxide and sodium methoxide.
  • Representative polar aprotic solvents include, but are not limited to, dimethylformamide (DMF), dimethylacetamide (DMA) and N-methyl-2-pyrrolidone (NMP).
  • cyclization can be carried out under a variety of conditions.
  • the cyclization can generally be carried out by the action of a mineral acid or an organic acid as defined above.
  • the cyclization step is performed in the presence of an organic acid, such as p-toluenesulfonic acid also in mixture with residual trifluoroacetic acid.
  • the reduction of the double bond of a compound of formula (VI) according to step iv) can be carried out by any catalytic hydrogenation procedure known in the art.
  • the hydrogenation can be carried out by using Pd/C and a source of hydrogen such as gaseous hydrogen (H 2 ) or hydrogen-donors in place of H 2 .
  • a source of hydrogen such as gaseous hydrogen (H 2 ) or hydrogen-donors in place of H 2 .
  • Representative "hydrogen-donors" include, but are not limited to, formic acid, sodium formate, ammonium formate and cyclohexene.
  • Deprotection of a compound of formula (VII) according to step v) gives the corresponding compound of formula (I).
  • Methods for the removal of hydroxyl protecting groups are known in the art; see, for example, Protective Groups in Organic Synthesis (T. Green and P. Wuts; 4th Edition; John Wiley and Sons, 2006).
  • deprotection of a compound of formula (VII) where the hydroxyl protecting group (PG) is tert-butyldimethylsilyl (TBDMS) can be accomplished by using Tetra-n-butylammonium fluoride (or TBAF) as a solution in tetrahydrofuran (THF).
  • THF Tetra-n-butylammonium fluoride
  • the compound of formula (II) can be prepared according to the general method for Fischer indole synthesis; for example, following the teachings reported in Scheme 1 and, in particular, Example 1(b) of EP 1296676.
  • the compounds of formula (IV) can be prepared, for example, following the teachings of B. Jiang et ah, Tetrahedron: Asymmetry 12 (2001) 2835-2843 (see, in particular, Scheme 1).
  • the compounds of formula (I) are useful intermediates for the preparation of the compound of formula (8A) as defined above.
  • the conversion of the compound of formula (I) wherein R is ethyl to the compound of formula (8A) can be carried out following the teaching of Example 8A of WO 2010/099039.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de préparation de dérivés d'indole de formule (I), dans laquelle R représente C1-4alkyle, utiles comme intermédiaires dans la production du récepteur homologue du récepteur du facteur chimiotactique exprimé sur des antagonistes du récepteur des cellules Th2 (CRTH2) utiles dans le traitement de divers troubles et maladies induits par la prostaglandine.
PCT/EP2013/071890 2012-10-18 2013-10-18 Procédé de préparation de dérivés d'indole WO2014060596A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12189104 2012-10-18
EP12189104.8 2012-10-18

Publications (1)

Publication Number Publication Date
WO2014060596A1 true WO2014060596A1 (fr) 2014-04-24

Family

ID=47018098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/071890 WO2014060596A1 (fr) 2012-10-18 2013-10-18 Procédé de préparation de dérivés d'indole

Country Status (1)

Country Link
WO (1) WO2014060596A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017005766A1 (fr) 2015-07-07 2017-01-12 Intervet International B.V. Procédé de production d'intermédiaires alcools tricycliques d'antagonistes de crth2
WO2017005759A1 (fr) 2015-07-07 2017-01-12 Intervet International B.V. Procédé pour produire des dérivés d'azaindole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234415A1 (en) * 2009-02-24 2010-09-16 Carl Berthelette Indole derivatives as crth2 receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234415A1 (en) * 2009-02-24 2010-09-16 Carl Berthelette Indole derivatives as crth2 receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN MAARSEVEEN J H ET AL: "An Approach to Canthine Derivatives Using the Intramolecular Pictet-Spengler Condensation", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 51, no. 16, 17 April 1995 (1995-04-17), pages 4841 - 4852, XP004221935, ISSN: 0040-4020, DOI: 10.1016/0040-4020(95)00169-9 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017005766A1 (fr) 2015-07-07 2017-01-12 Intervet International B.V. Procédé de production d'intermédiaires alcools tricycliques d'antagonistes de crth2
WO2017005759A1 (fr) 2015-07-07 2017-01-12 Intervet International B.V. Procédé pour produire des dérivés d'azaindole

Similar Documents

Publication Publication Date Title
JP5020848B2 (ja) Ｈｍ７４ａ受容体活性を有する薬剤
KR20200020877A (ko) 담즙산 유도체 제조를 위한 방법 및 중간체
MX2010013095A (es) Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
WO2009010988A1 (fr) Procédé amélioré, industriellement viable pour la préparation de palipéridone de haute pureté
JP5989900B2 (ja) ２−アミノ−４−アリールチアゾール化合物のアミド及びその塩類
BRPI0609632A2 (pt) preparo de famciclovir e outros derivados de purina
CN115884978A (zh) 制备胆酸衍生物的方法及其原料
CZ324292A3 (en) Quinoline derivatives, process of their preparation and pharmaceutical compositions in which said derivatives are comprised
WO2014060596A1 (fr) Procédé de préparation de dérivés d'indole
JP2011506601A (ja) ブプレノルフィンおよびブプレノルフィンの誘導体を調製するためのプロセス
CN110183445B (zh) 莫西沙星及其衍生物的合成方法
TW201708211A (zh) 具有 β 2受體激動及M3受體拮抗活性的苯並環衍生物及其在醫藥上的用途
EP0145207B1 (fr) Dérivés de la purine
EP0749438B1 (fr) Nouveaux composes silyle et leur utilisation
TW201829419A (zh) 製備3-經取代5-胺基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物之方法
CA3070853C (fr) Procedes de preparation d'acides biliaires
JP2002510691A (ja) プリン誘導体の製法およびその中間体
JP7308811B2 (ja) ステロイド系誘導体ｆｘｒアゴニストの製造方法
EP2348010B1 (fr) Méthode de production d'un composé tétrafluoro
JPH0680670A (ja) シクロプロパン誘導体及びその製造法
JPH0841035A (ja) シクロプロパン誘導体及びその製造法
WO2020148641A1 (fr) Procédé de préparation de 2-amino-5-hydroxy propiophénone
US5856337A (en) 2-arylquinolines and process for producing the same
JP2014532058A (ja) ５−［２−［７−（トリフルオロメチル）−５−［４−（トリフルオロメチル）フェニル］ピラゾロ［１，５−ａ］ピリミジン−３−イル］エチニル］−２−ピリジンアミンの製造方法
JP6051225B2 (ja) シクロプロパン誘導体の調製方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13785386

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13785386

Country of ref document: EP

Kind code of ref document: A1